Generation of antitumor response by IL-2-transduced JAWS II dendritic cells

Immunobiology

Volumn 216, Issue 10, 2011, Pages 1074-1084

  Rossowska, Joanna ^a   Pajtasz Piasecka, Elzbieta ^a   Ryśnik, Oliwia ^a   Wojas, Justyna ^a   Krawczenko, Agnieszka ^a   Szyda, Anna ^a   Duś, Danuta ^a  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

Antitumor immunotherapy; Cell vaccination; Experimental MC38 colon carcinoma; IL 2 Transduced dendritic cells

Indexed keywords

DENDRITIC CELL VACCINE; GAMMA INTERFERON; INTERLEUKIN 2; PROTEIN TAG; RETROVIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CANCER IMMUNOTHERAPY; CANCER INFILTRATION; CANCER INHIBITION; CANCER SURVIVAL; CANCER TISSUE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MIGRATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; FEMALE; IL2 GENE; MOUSE; NATURAL KILLER T CELL; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL MOVEMENT; COLONIC NEOPLASMS; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; FEMALE; IMMUNITY, CELLULAR; IMMUNOPHENOTYPING; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; KAPLAN-MEIER ESTIMATE; LYMPH NODES; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; PHENOTYPE; TH1 CELLS; TRANSDUCTION, GENETIC;

EID: 80052090061     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2011.05.006     Document Type: Article

References (36)

1. Akiyama Y., Maruyama K., Watanabe M., Yamaguchi K. Retroviral-mediated IL-12 gene transduction into human CD34+ cell-derived dendritic cells. Int. J. Oncol. 2002, 21:509-514.
2. Akiyama Y., Watanabe M., Maruyama K., Ruscetti F.W., Wiltrout R.H., Yamaguchi K. Enhancement of antitumor immunity against B16 melanoma tumor using genetically modified dendritic cells to produce cytokines. Gene Ther. 2000, 7:2113-2121.
3. Alter G., Malenfant J.M., Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J. Immunol. Methods 2004, 294:15-22.
4. Betts M.R., Koup R.A. Detection of T-cell degranulation: CD107a and b. Methods Cell Biol. 2004, 75:497-512.
5. Brossart P., Goldrath A.W., Butz E.A., Martin S., Bevan M.J. Virus-mediated delivery of antigenic epitopes cells as a means to induce CTL. J. Immunol. 1997, 158:3270-3276.
6. Butz E.A., Bevan M.J. Differential presentation of the same MHC class I epitopes by fibroblasts and dendritic cells. J. Immunol. 1998, 160:2139-2144.
7. De Vries I.J., Krooshoop D.J., Scharenborg N.M., et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res. 2003, 63:12-17.
8. Eggert A.A., Van Der Voort R., Torensma R., et al. Analysis of dendritic cell trafficking using EGFP-transgenic mice. Immunol. Lett. 2003, 89:17-24.
9. Fong L., Engleman E.G. Dendritic cells in cancer immunotherapy. Ann. Rev. Immunol. 2000, 18:245-273.
10. Gaffen S.L., Liu K.D. Overview of interleukin-2 function, production and clinical applications. Cytokine 2004, 28:109-123.
11. Gattinoni L., Powell D.J., Rosenberg S.A., Restifo N.P. Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol. 2006, 6:383-393.
12. Granucci F., Zanoni I., Feau S., Ricciardi-Castagnoli P. Dendritic cell regulation of immune responses: a new role for interleukin 2 at the intersection of innate and adaptive immunity. EMBO J. 2003, 22:2546-2551.
13. Hoyer K., Dooms H., Barron L., Abbas A.K. Interleukin-2 in the development and control of inflammatory disease. Immunol. Rev. 2008, 226:19-28.
14. Huck S.P., Tang S.C., Andrew K.A., et al. Activation and route of administration both determine the ability of bone marrow-derived dendritic cells to accumulate in secondary lymphoid organs and prime CD8+ T cells against tumors. Cancer Immunol. Immunother. 2008, 57:63-71.
15. Indrová M., Pajtasz-Piasecka E., Jandlová T., Símová J., Bubeník J., Radzikowski C. IL-2 gene-modified tumour vaccines: monitoring of IL-2 levels in serum and peritoneal cavity of vaccinated mice. Folia Biol. (Praha) 1999, 45:7-11.
16. Jiang X., Shen C., Rey-Ladino J., Yu H., Brunham R.C. Characterization of murine dendritic cell line JAWS II and primary bone marrow-derived dendritic cells in Chlamydia muridarum antigen presentation and induction of protective immunity. Infect. Immunity 2008, 76:2392-2401.
17. Kradin R.L., Xia W., Pike M., Byers H.R., Pinto C. Interleukin-2 promotes the motility of dendritic cells and their accumulation in lung and skin. Pathobiology 1996, 64:180-186.
18. Kusnierczyk H., Pajtasz-Piasecka E., Koten J.W., Bijleveld C., Krawczyk K., Den Otter W. Further development of local IL-2 therapy of cancer: multiple versus single IL-2 treatment of transplanted murine colon carcinoma. Cancer Immunol. Immunother. 2004, 53:445-452.
19. Kusnierczyk H., Pajtasz-Piasecka E., Radzikowski C. Synergistic antitumour effects of chemo-immunotherapy with an oxazaphosphorine drug and IL-2-secreting cells in a mouse colon cancer model. Med. Oncol. 1999, 16:267-278.
20. Lappin M.B., Weiss J.M., Delattre V., et al. Analysis of mouse dendritic cell migration in vivo upon subcutaneous and intravenous injection. Immunology 1999, 98:181-188.
21. Martin-Fontecha A., Sebastiani S., Hopken U.E., et al. Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J. Exp. Med. 2003, 198:615-621.
22. Mendoza L., Bubeník J., Símová J., Jandlová T., Vonka V., Mikysková R. Prophylactic, therapeutic and anti-metastatic effects of BMDC and DC lines in mice carrying HPV 16-associated tumours. Int. J. Oncol. 2003, 23:243-247.
23. Mendoza L., Bubeník J., Símová J., Korb J., Bieblová J., Vonka V., Indrová M., Mikysková R., Jandlová T. Tumour-inhibitory effects of dendritic cells administered at the site of HPV 16-induced neoplasms. Folia Biol. (Praha) 2002, 48:114-119.
24. Mocellin S., Wang E., Marincola F.M. Cytokines and immune response in the tumor microenvironment. J. Immunother. 2001, 24:392-407.
25. Mullins D.W., Engelhard V.H. Limited infiltration of exogenous dendritic cells and naive T cells restricts immune responses in peripheral lymph nodes. J. Immunol. 2006, 176:4535-4542.
26. Ogawa F., Iinuma H., Okinaga K. Dendritic cell vaccine therapy by immunization with fusion cells of interleukin-2 gene-transduced, spleen-derived dendritic cells and tumour cells. Scand. J. Immunol. 2004, 59:432-439.
27. Ojima T., Iwahashi M., Nakamura M., Matsuda K., Naka T., Nakamori M., Ueda K., Ishida K., Yamaue H. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen. Int. J. Oncol. 2006, 28:947-953.
28. Pajtasz-Piasecka E., Indrová M. Dendritic cell-based vaccines for the therapy of experimental tumors. Immunotherapy 2010, 2:257-268.
29. Pajtasz-Piasecka E., Rossowska J., Szyda A., Krawczenko A., Dus D. Generation of anti-tumour response by JAWS II mouse dendritic cells transduced with murine interleukin 12 genes. Oncol. Rep. 2007, 17:1249-1257.
30. Palucka A.K., Laupeze B., Aspord C., Saito H., Jego G., Fay J., Paczesny S., Pascual V., Banchereau J. Immunotherapy via dendritic cells. Adv. Exp. Med. Biol. 2005, 560:105-114.
31. Parmiani G., Rivoltini L., Andreola G., Carrabba M. Cytokines in cancer therapy. Immunol. Lett. 2000, 74:41-44.
32. Rossowska J., Pajtasz-Piasecka E., Szyda A., Krawczenko A., Zietara N., Dus D. Tumour antigen-loaded mouse dendritic cells maturing in the presence of inflammatory cytokines are potent activators of immune response in vitro but not in vivo. Oncol. Rep. 2009, 21:1539-1549.
33. Rossowska J., Pajtasz-Piasecka E., Szyda A., Zietara N., Dus D. Tissue localization of tumor antigen-loaded mouse dendritic cells applied as an anti-tumor vaccine and their influence on immune response. Folia Histochem. Cytobiol. 2007, 45:349-356.
34. Steinman R.M., Banchereau J. Taking dendritic cells into medicine. Nature 2007, 449:419-426.
35. Tuyaerts S., Aerts J.L., Corthals J., Neyns B., Heirman C., Breckpot K., Thielemans K., Bonehill A. Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol. Immunother. 2007, 56:1513-1537.
36. Zhong H., Shurin M.R., Han B. Optimizing dendritic cell-based immunotherapy for cancer. Expert. Rev. Vaccines 2007, 6:333-345.